Migration Letters

Volume: 21, No: S3 (2024), pp. 1305-1316

ISSN: 1741-8984 (Print) ISSN: 1741-8992 (Online)

www.migrationletters.com

Narrative Review Of Diabetic Ketoacidosis Management In Adults From Various Major Guidelines

Mabrouk AL-Rasheedi[1,2], Baharudin Ibrahim*[1,3], Khawaja Husnain Haider[4], Hadzliana Zainal[1]*

Abstract

Diabetic ketoacidosis is the most prevalent acute hyperglycaemic emergency in diabetes mellitus, leading to significant morbidity and mortality. Patients with diabetes are at higher risk of death due to DKA than any other type of acute hyperglycaemia emergency. The most common precipitating causes of DKA include infections, a new diagnosis of diabetes, and nonadherence to insulin therapy. Despite the availability of several guidelines for managing diabetic ketoacidosis, there is a lack of comprehensive synthesis of the summary of the evidence recommendations for optimal control of DKA. This review critically scoped the major guidelines used internationally for managing DKA. This review gives an overview of the most recent guidelines for treating DKA in adults. It does this by looking at the main guidelines and focusing on the most recent changes that are specific to treating DKA and the English language used in these guidelines. The hallmarks of DKA are hyperglycaemia, ketoacidosis, dehydration, and electrolyte imbalance. Early diagnosis and timely treatment are the primary essentials for achieving better patient outcomes. The major components of therapeutic intervention encompass a comprehensive approach. The mainstays of therapy include restoration of circulating volume by fluid replacement to rehydrate the body and restore electrolyte balance, insulin therapy is administered to lower blood sugar levels and stop the production of ketones, electrolyte replacement, especially with particular importance on potassium balance in blood regular monitoring of blood glucose, electrolytes, and acid-base balance is essential to track the progress of treatment, and treatment of any underlying precipitating event that triggers DKA occurrence in diabetic patients. Discharge plans should consist of appropriate insulin regimens and interventions to prevent the recurrence of DKA through many therapeutic strategies. Encompass comprehensive patient education on insulin administration and self-management, the promotion of lifestyle modifications to regulate glucose levels.

Keywords: *Diabetic ketoacidosis, diabetes mellitus, metabolic, acidosis, insulin. Guidelines.*

1. Introduction

Diabetic ketoacidosis (DKA) is an acute complication of uncontrolled diabetes mellitus associated with increased m[1]orbidity and mortality[1]. DKA prevalence in patients with newly diagnosed type 1 diabetes (T1DM) varies depending on the country [1]. The rates of DKA in clinically diagnosed cases of T1DM are variable; 17.9% in Denmark, 24.8% in Kuwait, 25.6% in Canada, 35.2% in Germany, and 80% in the United Arab Emirates [2-4].

1-School of Pharmaceutical Sciences, Universiti Sains Malaysia, Malaysia.
2- Albukairyah General Hospital, Ministry of Health, Albukairyah, Saudi Arabia.
3-Faculty of Pharmacy, Universiti Malaya, Malaysia.
4-Department of Basic Sciences, Sulaiman AlRajhi University, Albukairiyah, Saudi Arabia.
*Corresponding author

Within the past few years, there has been a discernible rise in hospitalizations associated with DKA worldwide[3]. Despite the significant advancements in identifying and treating DKA, it is still a leading cause of hospitalization and death in children and adults, especially in less-developed nations [4]. The presence of psychiatric illnesses, lower socioeconomic class, poor glycaemic control, and female gender are the predictors of DKA admission to hospitals that have been documented the most frequently[4].

DKA is also the foremost underlying cause of death among young T1DM patients under twenty-four years[5]. The fatality rates associated with DKA have dramatically declined over the past century, from over 90% before insulin discovery in 1922 to 3-10% by 1974[2]. The current DKA-related in-hospital mortality rates in developed nations are generally modest, at less than 1-2.5%[6]. Studies from less-developed nations have shown that individuals hospitalized with DKA have fatality rates ranging from 10-30% [5, 7].

Numerous medical institutions across the United States of America, Europe, and Australia have acknowledged and released guidelines for managing diabetic ketoacidosis (DKA)[7]. These comprehensive guidelines cover pathogenesis, diagnosis, treatment modalities, clinical assessment methodologies, and monitoring strategies for diabetes care[8]. They include the American Diabetes Association Standards of Medical Care in Diabetes (ADA), the American Association of Clinical Endocrinology (AACE), the National Institute for Health and Care Excellence [3] Clinical Guidelines (United Kingdom), the European Association for the Study of Diabetes (EASD) Guidelines (Europe), the Canadian Diabetes Association Clinical Practice Guidelines (Canada), and the Australian Diabetes Society (ADS) Guidelines (Australia). These guidelines are based on the latest scientific evidence. These guidelines are updated regularly to ensure healthcare professionals can access the most current information on managing DKA. It's worth noting that number of other guidelines and protocols are referenced in those international guidelines.

2-Methodology

This narrative review's primary focus is critically appraising the multiple professional guidelines and expounding a narrative assessment of DKA management in adult patients. A scoping literature review was conducted by searching using any DKA words in the major guidelines. All guidelines were reviewed thoroughly to ensure that they were relevant to the topic at hand by analysing the content of each guideline. The selected sources were then read in detail and analysed. An organized summary was created, highlighting the main findings and themes. This review will serve as a valuable and comprehensive source of information for researchers, academics, and clinicians who are involved in caring for and managing such cases.

3. Clinical Presentation of DKA

DKA is characterized by a wide variety of gastrointestinal symptoms, most of which are treatable and include nausea, abdominal discomfort, and vomiting[9]. DKA typically appears clinically with signs and symptoms of hyperglycaemia, including increased thirst, urination, fatigue, and weight loss[9]. In extreme situations, the symptoms of acidosis might include drowsiness, confusion, consciousness loss, and breathing compromise[10]. These symptoms can also occur when awareness is lost[10].

DKA is caused by a diverse array of factors, including infections (especially urinary tract infections and pneumonia), a recent diagnosis of diabetes, poor compliance or inappropriate insulin dosing, cardiovascular pathologies (mainly heart attack and stroke), trauma, acute pancreatitis, burns, surgical intervention, prescription drugs (especially atypical antipsychotics, thiazides, and beta-blockers); mental disorders (depression and eating disorders), and drug abuse[11] . Oral antihyperglycemics, i.e., sodium-glucose co-transporter 2 inhibitors, are also linked to the onset of DKA. If a patient taking one of these

medications' experiences nausea, abdominal discomfort, vomiting, or lethargy, the doctor should be alerted to the risk of developing DKA[12].

The patient's mental health and physical status should be evaluated during the physical examination, and a focused and methodical analysis is warranted[12]. Patients typically present initially with volume depletion symptoms, including palpitations, hypotension, dry oral mucosa, and reduced skin turgor[13]. In the presence of an illness, an average or even mildly elevated temperature may be presented primarily due to peripheral vasodilation[12]. Changes in psychological state, coma, and shock are other potential outward manifestations of Kussmaul respirations, which are characterized by rapid and deep breathing, besides a fruity breath odor [14] summarized in table 1.

Table1: - Summary of key signs and symptoms of diabetic ketoacidosis

Clinical history	Clinical signs	Biochemistry	Potential triggers
Polyuria/ polydipsia	Dehydration	Hyperglycaemia (>11mmol/L)	Infection, e.g., viral
Weight loss	Kussmaul breathing	Acidaemia (pH<7.3)	Interruption to insulin therapy, e.g., pump malfunction or emitted doses
Abdominal pain	Ketotic smell	Ketosis (blood ketones >3mmol/L or urine ketones++)	Physical or emotional trauma
Weakness	Lethargy, drowsiness		Pregnancy
Vomiting			Drug interactions including alcohol and particularly cocaine
Confusion			

4. Diagnostic Criteria for DKA

Hospitalization coding is the gold standard for epidemiological purposes due to the high prevalence of in-hospital DKA. T1DM patients account for 66% of all adult DKA cases, while T2DM patients account for 34%[14] .

The treating Physicians should order investigations to identify the triggering variables wherever possible[15]. These variables may include urine glucose, ketones, and a complete blood count (CBC) besides blood urea nitrogen (BUN), creatinine, calcium, magnesium, phosphate, and uric acid analysis[16]. Additionally, arterial blood gas (ABG) analysis and electrocardiogram (ECG) should be carried out to exclude; electrolyte disturbances that may predispose to dysrhythmia [8].

For a proper diagnosis, the following biochemical parameters must be met: Negative serum ketones or substantial ketonuria (less than or equal to 2+ urine ketone) and; venous or arterial bicarbonate less than 15 mmol/L and pH less than 7.3; and BG less than or equal 200 mg/dl (11.1 mmol/L) or known DM [16].

Severity of DKA	Arterial or venous pH	Glucose (mg/dl)	Bicarbonate (mmol/l)	β-hydroxybutyrate (mmol/l)	Urine or serum ketones (nitroprusside test)	Anion gap (mmol/l)	Mental Status
American Diabetes Association (ADA)d Criteria For Adults [9]							
Mild	7.25-7.30	>250	15-18	>3.0	Positive	>10	Alert
Moderate	7.24-7.0	>250	10-15	>3.0	Positive	>12	Alert/drowsy
Severe	<7.0	>250	<10	>3.0	Positive	>12	Stupor/coma
Joint British Diabetes Societies for Inpatient Care [11]							
NA	<7.30*	>200	<15	>3.0	Positive	NA	NA
National Institute for Health Care Excellence (2023)							
Mild	7.3	200	15	>3.0	Positive	NA	NA
Moderate	7.2	200	10	>3.0	Positive	NA	NA
Severe	7.1	200	5	>3.0	Positive	NA	NA
American Association of Clinical Endocrinology (2023)							
NA	NA	NA	NA	NA	NA	NA	NA
European Association for the Study of Diabetes (2023)							
NA	NA	NA	NA	NA	NA	NA	NA
Australian Diabetes Society (2018)							
Mild	NA	>270	NA	NA	Positive	NA	Coma
Moderate							
Severe							
Canadian Diabetes Association Clinical Practice (2018)							
Mild	NA	NA	NA	NA	NA	NA	NA
Moderate							
Severe							

Table 2: DKA Diagnostic Criteria depends on major guidelines.

DKA symptoms are manifested when hyperglycemia, metabolic acidosis, and ketosis occur concomitantly[17]. According to ADA and the Joint British Diabetes Societies for Inpatient Care, the primary diagnostic characteristics of DKA are the elevation in circulating complete blood ketone proportion. The other clinical manifestations are serum glucose level and bicarbonate concentration (Table 2) [9-11]. to 8.7 % of patients with DKA present

with average or only slightly elevated blood glucose readings (less than 13.9 mmol/l (250 mg/dl)) [12]. These studies have linked prolonged fasting, excessive alcohol consumption, inappropriate insulin dosing, pregnancy, and the consumption of an SGLT2 inhibitor of the observed euglycemic DKA and some guidelines gathering [13].

According to the published data regarding euglycemic DKA, approximately 3%

Arterial or venous pH measurements are recommended by the ADA criteria for diagnosis, determining the requirement for bicarbonate therapy, and monitoring resolution. An individual's acidity and awareness level, not their blood sugar or ketones, determine the severity of DKA. NA, not applicable. *Venous pH can be used to diagnose DKA.
Hence, a comprehensive medical history is essential for verifying DKA diagnosis in patients on SGLT2 inhibitors, as these patients present with DKA despite being without severe hyperglycemia [6]. Admitting biochemistry in euglycemic DKA is sometimes non-specific, depending on the factors such as the patient's level of respiratory tolerance, a mixed acid-base imbalance, and other clinical manifestations [18]. Adrogué et al. reported that 46 % of patients (aged 14 to 55 years) hospitalized for DKA were observed to have severe anion gap acidosis, 43 % had combined anion gap acidosis and hyperchloraemic metabolic acidosis, and 11% with hyperchloraemic metabolic acidosis[19]. However, the information describing acidity patterns upon admission was scarce; hence, the distinctions between these groups did not influence their prompt treatment or diagnosis of DKA[6]. A heterogeneous collection of biochemical anomalies characterizes DKA, evidenced by the failure to group the affected patients [6]. The most common occurrence of hyperchloremic metabolic acidosis is observed in patients who received large volume infusions of 0.9 % sodium chloride solution during hospitalization[20]. The level of ketonemia, accumulation of ketones in the blood, can be determined through the use of the nitroprusside reaction in serum or urine, as well as through the precise measurement of beta-hydroxybutyrate in blood capillaries, either at the point of prevention or in the laboratory of a hospital [9, 17]. The nitroprusside test is only but straightforward measures acetoacetate without revealing beta-hydroxybutyrate, a primary ketone in DK[21]. Since acetoacetate level in urine or plasma only contributes 15 to 40 % of the total ketone quantity, focusing on acetoacetate when doing urine ketone testing by itself is probably underestimating the prevalence of ketonemia [10, 22]. Additionally, several sulfhydryl drugs, i.e., captopril and medicines such as valproate, which have been prescribed for comorbidities (epilepsy or hypertension), may contribute to false-positive results—Nitroprusside urine testing [10]. On the same note, expired test strips might produce false-negative findings. This can also happen when urine specimens are slightly alkaline, such as safely consuming a large quantity of vitamin C[23]. The Joint British Diabetes Societies for Inpatient Care strongly discourages urine ketone testing and alternatively suggests beta-hydroxybutyrate analysis in patients' blood sample as the method of choice for assessing ketonemia in both outpatient and inpatient settings [6]. As evaluated by serum bicarbonate level, the incidence of acidaemia has a strong association with beta-hydroxybutyrate in patients with DKA [24]. Bicarbonate levels of 15.0 and 18.0 mmol/l correlate to 3.0 and 4.4 mmol/l of beta-hydroxybutyrate, respectively, suggesting that a 'best estimate' can be formed based on the bicarbonate concentration even when plasma ketone measurements are not available [6]. It is pertinent to mention that beta-hydroxybutyrate testing is also helpful in therapy progress monitoring[25]. If the plasma levels of beta-hydroxybutyrate do not drop by 0.5 mmol/l/hour after intravenous insulin and fluid, the guidelines from the United Kingdom advocate ramping up the treatment [11, 15]. Many patients who experience hyperglycaemic crises have a combination of signs and symptoms of DKA and hyperglycaemic hyperosmolar state (HHS). In a study involving 1,211 participants who were first time hospitalized for hyperglycaemic crises meeting the requirements of ADA, there was a significant reduction in the risk of death [9], 465 individuals (38 %) were diagnosed with isolated DKA, 421 individuals (35 %) were diagnosed with isolated HHS, and 325

individuals (27 %) were diagnosed with combination DKA and HHS symptoms[26]. Patients with combined DKA–HHS had greater in-hospital death rates than patients with isolated DKA, even after adjusting for sex, age, ethnicity, BMI, and the Charlson Comorbidity Index score (which anticipates the one-year mortality of a patient with a range of comorbidities). The adjusted odds ratio was 2.7, and the 95% confidence interval ranged from 1.4 to 4.9 [19].

A further hyperglycaemic emergency that may be experienced is the HHS, which happens less frequently than DKA (less than 1% of all diabetes-related crises) but with a significant (up to 20%) fatality rate [21]. In patients with HHS, significant hyperglycemia and elevated serum osmolality (a measure of serum electrolyte and hyperglycemia) [20] with a concomitant decrease in the quantity of blood in the circulatory system [27]. Insulin level in HHS patients is sufficient to suppress ketogenesis but falls short of enough to enable optimal glucose absorption by cells[25]. Therefore, HHS's hallmarks are osmotic diuresis and hyperglycemia, which do not result in ketosis. These symptoms contribute to continuous dehydration[24] . A simultaneous disease, i.e., acute coronary syndrome or infection, might cause a rise in defence hormones and worsening hyperglycemia. Nevertheless, this is quite analogous to what goes on during DKA. Atypical antipsychotics and corticosteroids are two medications that can bring on HHS [23, 28].

The biochemical trifecta of ketonemia/ketonuria, hyperglycemia, and significant anion-gap metabolic acidosis is used to diagnose DKA[24]. Since DKA is potentially fatal, early diagnosis and therapeutic intervention are required[24]. T1DM patients are more likely to develop DKA if they contract an infection, fail to take their insulin as directed regularly, or are under significant emotional or psychological stress[29]. DKA is a common symptom observed in newly diagnosed patients with T1DM, whereas patients with T2DM can develop DKA if they have prolonged uncontrolled hyperglycemia or stress[29]. It is recommended to test for ketone bodies whenever there is a suspicion of DKA or when the blood glucose (BG) level is less than or equal to 14 mmol/1 in people with T1DM[29]. All ketone-positive diabetic patients suspected of DKA must be taken to the emergency room for additional evaluation and treatment [24, 25].

The diagnostic criteria for HHS differ slightly between the United Kingdom and the United States [9, 26]. The recommendations in the United Kingdom classify HHS as having a glucose level that is lower than 30 mmol/l, a pH that is higher than 7.3, a bicarbonate quantity that is higher than 15 mmol/l, and a blood beta-hydroxybutyrate level that is 320 mOsmol/l ; meanwhile, the criteria of the United States defined HHS as having glucose levels > 33.3 mmol/l, pH > 7.3, and a bicarbonate > 18 mmol/l, characterized by low levels of ketones in the serum or urine and an osmolality > 320 mOsmol/l [22, 30]. For HHS management, it is essential to identify and treat any precipitating cause, address and rectify any fluid deficiencies, i.e., potassium replacement, and bring the patient's hyperosmolality level normal. Using intravenous fluids, including 0.9 % normal saline, would help reduce glucose levels by treating haemoconcentration (a rise in the ratio of red blood cells in the body due to dehydration) and recovering liver function. When dealing with HHS patients, the volume loss in the circulation is often more severe than coping with DKA; hence, more effective fluid administration rates are usually required. Because there have not been enough clinical tests, the recommendations that different organizations' consensuses have reached are slightly diverse [9]. If there are signs of metabolic acidosis, intravenous insulin treatment should be started as soon as the initial fluid bolus has been administered (HHS and DKA commonly co-exist) [19]. Nevertheless, in the absence of acidosis, an intravenous insulin administration at a weight-based constant rate is not started until the glucose level stops falling, even after the fluid replacement has been performed alone or after adjustments have been made to the potassium concentrations [9].

5. Management of DKA

Restoration of circulatory volume, tissue perfusion, resolution of hyperglycemia, and correction of acidosis and electrolyte levels are the most important goals of treatment. The World Health Organization recognizes insulin and 0.9 % saline solution as life-saving medications [27]. It is also essential to address any underlying cause of DKA, such as infection, stress, etc. [20]. Rehydration, insulin injection, maintaining an electrolyte balance—primarily potassium—and identifying and treating the precipitating event are therapy modalities' primary focus for DKA. The DKA treatment requires careful monitoring of the patient's BG level, hydration status, electrolyte levels, and acidity [8, 11, 26].

Rehydration

Rehydration begins with a normal saline bolus and then progresses to a rapid infusion of normal saline taking care of cerebral edema and overhydration)[31]. In cases of hyperglycemia, it may be essential to treat pseudo hyponatremia by administering extra sodium (3 Na+ for every 10 mmol/L of glucose)[32]. In the first hour, a fluid replacement of isotonic saline is administered at 15-20 ml/kg body weight per hour (1-1.5 L)[32]. Hydration levels, serum electrolyte concentrations, and urine production together are essential in determining the fluid that should be used to replenish lost fluids. Patients with hypernatremia can benefit from an infusion of 0.45 % Na Cl at 4-14 ml/kg/hour, whereas those with hyponatremia or eunatremia should receive 0.9 percent Na Cl at a comparable rate[24]. The goal for the next 12–24 hours is to replace fifty percent of the expected water shortage[26]. The approach is not designed for hemodynamically unstable patients; therefore, the intensive care unit team must manage these patients[11]. When treating patients with hypotension, intensive fluid therapy using isotonic saline should be continued until the patient's blood pressure is stable [11, 25, 26].

Switch from 0.9% sodium chloride to 0.45% sodium chloride once hypertension has been treated (with potassium chloride)[11]. Maintain intravenous fluids at a greater osmolality. However, if plasma osmolality is lowering more quickly than 3 mmol/kg/hour and the adjusted plasma sodium is decreased (i.e., may need to maintain on normal saline)[11].

Summary of intravenous fluid

1- Administer 0.9% sodium chloride (IV) initially. Give 1 to 2 L/hour to the person if they are in shock; otherwise, give 500 mL/hour for 4 hours, then 250 mL/hour for 4 hours, and then as needed.
2- Add potassium immediately if a person is normo-hypokalaemia. If you are initially hyperkalemia, you should only add potassium after your serum potassium level drops to between 5 and 5.5 mmol/L and you start to urinate.
3- Add more glucose to keep plasma glucose between 12.0 and 14.0 mmol/L until it reaches 14.0 mmol/L.

Potassium

After establishing diuresis, supplementation should be initiated for plasma potassium levels below 5.0 to 5.2 mmol/L[33]. However, this is often done with the second litter of saline solution[33]. To avoid hypokalaemia, it is essential to begin the replacement process once the level drops below the standard upper limit[34]. Suppose the patient is brought in with potassium levels that are either normal or low. In that case, the administration of potassium could begin immediately, with values in the IV fluid ranging from 10 to 40 mmol/L and a maximum proportion of 40 mmol/h. Insulin, correction of acidosis, and rehydration decrease the serum potassium concentration[8]. In the case of serum potassium <3.3

mmol/L by replacement at 40 mmol/L. Additionally, the potassium deficiency of HHS should be addressed similarly [8, 11, 26].

Patients diagnosed with DKA who have experienced extensive vomiting or have been taking diuretics may appear with significant hypokalemia[8]. In these situations, potassium replacement may start with fluid therapy and insulin administration should be delayed until the potassium level reaches more than 3.3 milliequivalents per liter (Table 3). Thus, this is done to prevent respiratory and arrhythmia muscle spasms[11]. During the treatment of DKA, it is essential to accurately monitor the patient's potassium levels [8, 11, 25, 26, 29].

Table 3:- Summary of Potassium management depend on ADA guidelines 2023.

Level of K more than 5.2 mmol/L	Level of K from 3.3 to 5.2 mmol/L	less than 3.3 mmol/L (Close monitoring)
Follow the patient and monitoring	40 mmol/L To be added to IV fluid, don't exceed the maximum rate of 10 meq/potassium chloride per hour	Hold insulin infusion for 2 hours or until serum potassium is more than or equal to 3.3 meq/L 1- Perform ECG 2-Apply cardiac monitor to the patient 3- Increase the rate of potassium chloride infusion but don't exceed the maximum rate of 10 meq/potassium chloride per hour. 4-Request a higher potassium chloride concentration infusion from Pharmacy. 5-Once ready, give 40 meq of potassium chloride in 500 ml 0.9 % normal saline to run over 4 hours. 6-Resume insulin infusion when serum potassium exceeds or exceeds 3.3 mmol/L.

Phosphate replacement

In most cases, the serum phosphate quantities are expected when the condition is first presented; however, intracellular deficiency is observed, and serum concentrations drop as DKA treatment progresses. Patients with serum phosphate concentrations below 1.0-1.5 mg/dl (0.3-0.5 mmol/l) must receive phosphate replacement [9, 11].

However, it has been suggested that the addition of phosphate to the infusion will reduce the risk of hypophosphatemia, which has been linked to several severe symptoms in certain patients, such as rhabdomyolysis (the collapse of body muscles), hemolytic anemia, renal failure, arrhythmias, and respiratory failure [30-33]. Phosphate replacement should be actively considered for patients suffering from heart malfunction, anemia, or respiratory depression. The biggest worry about phosphate replacement is that it can cause hypocalcemia; however, studies showing this side effect have done so by replacing calcium with phosphate at a higher rate than is now advised in protocols 192[34]. During treatment, phosphate concentrations ought to be checked at least once every four to six hours, but checking more frequently (once every two to three hours) is advised for patients who are not getting their phosphate levels replaced [6].

Insulin

If the patient's potassium level is below 3.3 mmol/L, insulin should not be administered. In adults, a starting bolus of five to ten units of regular or short-acting insulin (or 0.2 units per kilogram) is administered intravenously (controversial – may start with infusion). After completion, a continuous infusion of five to ten U (or 0.1 U/kg) every hour will be administered[35]. When the blood glucose level drops below 14.0 mmol/L, add five percent dextrose to the intravenous fluids to prevent hypoglycemia. Bicarbonate is not administered to the patient unless the patient is at risk of passing away or going into shock (typically a pH level lower than 7.0)[36]. Once the serum level of potassium reaches more than 3.3 mEq/l, the patient may begin treatment with intravenous insulin. This treatment should be maintained until the patient is no longer in DKA and can be switched to insulin administered subcutaneously [8, 11, 25, 26, 29, 35].

Subcutaneous insulin injections are sometimes used to treat patients with uncomplicated DKA brought into the emergency or step-down units. In the case of subcutaneous insulin therapy, they ensure enough fluid replacement, frequent point-of-care blood glucose monitoring, treatment of any concurrent infections, and appropriate follow-up to circumvent recurrent DKA episodes [37]. In addition, a literature assessment of five randomized clinical studies, including patients with DKA, revealed no significant difference between subcutaneous rapid-acting insulin analogues and conventional intravenous insulin [36]. Hypoglycaemic episodes were the primary adverse impact of both treatments.

Switch to subcutaneous insulin.

When the patient's venous bicarbonate level is ≥18 mmol/L or the patient's pH level is ≥7.3, the anion gap has been closed, and the patient can begin taking it orally. The insulin infusion should be continued for an additional hour after the initial rapid-acting insulin dose [8, 11, 25, 26, 29]. To switch from intravenous successfully and effectively to subcutaneous insulin and prevent a repeat of DKA and rebound hyperglycemia, basal insulin should be administered 2-4 hours before stopping the intravenous insulin. When used with strict fluid management to treat mild or moderate DKA, there is no detectable difference in results for intravenous human regular insulin and subcutaneous rapid-acting analogs [20].

Bicarbonate

The healthcare professional should consider adding bicarbonate if the patient's pH is below 6.9. To do so, 50 millimoles of sodium bicarbonate dilutes in 200 milliliters of water should be infused at 200 milliliters per hour. After that, bicarbonate infusions should be repeated every two hours until the pH reaches > 6.9[37]. While receiving a bicarbonate infusion, the patient's potassium should be monitored twice hourly [8, 11, 26, 29].

6. Quality of Life

The National Institute for Health and Care Excellence in the United Kingdom [3] comprehensively evaluated the available research on treating DKA. It concluded that no studies on adults assess the quality of life [33]. However, the worry of developing DKA is one of the variables that lowers a person's quality of life when they have T1DM [11]. It is important to stress that recurring DKA does not contribute to additional losses in quality of life for people with T1DM, even though people with T1DM experience a decreased quality of life [11]. Reduced quality of life can result from the onset of any systemic or neurological injury, making preventing such problems essential [34]. As was previously indicated, managing DKA is not cheap [35]; these costs impose enormous difficulties not only on the individuals who must pay for them themselves but also on society as a whole [37].

6. Prevention of Admission and Readmission

Additional techniques for protecting recurring episodes of DKA include a higher level of intensive collaboration of treatment with patients and an improved level of parental involvement[37]. Youth who have had several hospitalizations due to DKA are targeted by the prevention measure of the Novel Interventions in Children's Healthcare program, which makes use of coordinated care with both the parents and telehealth [6, 36]. This investigation showed that frequent contact with teenagers through texting and other kinds of engagement reduced the number of readmissions for DKA. In addition, the T1DM Exchange program has demonstrated that the utilization of modern technologies, including insulin injections and real-time continuous measurement of glucose, could be beneficial in the prevention of recurring DKA episodes [37-39]. In the 1990s, continuous subcutaneous insulin infusion (CSII) or insulin injections were connected with a significantly higher risk of DKA in people with T1DM, including children and adults[12] . Nevertheless, a series published in 2017 revealed a low prevalence of 1.0 cases per one hundred patient years [14]. Patients who were treated with continuous subcutaneous insulin infusions had a reduced risk of DKA compared to patients who were treated with multi-dose subcutaneous insulin injections, according to an analysis of 13,487 respondents (years of age two to 26 years) in the T1DM Exchange clinic registry[11]. Nevertheless, because these people with diabetes were cared for in specialized diabetes centers in the United States, the prevalence of DKA among those treated in different centers could be higher[24]. Comparable results were found in a German trial with T1DM; those using CSII had much lower rates of DKA compared with those who received injections of insulin (2.29 versus 2.80 per 100 patient-years) , indicating that expanding CSII use may represent a new approach to decreasing the prevalence of DKA. Moreover, a pump is costly and can only be done in expertly equipped canters[37]. A disproportionate incidence of recurring DKA episodes can be attributed to patients with issues adhering to their treatment [23]. In people diagnosed with T2DM in the United States, noncompliance with treatment is the cause of around 80 percent of recurring DKA episodes and is responsible for 50 percent of first DKA events[11]. In the United Kingdom, persons who had participated in a diabetes training program and were taking insulin according to a variable basal-bolus dosage regimen based on individualizing carbohydrate proportions at every meal had a 61 percent lower chance of developing DKA [37]. Likewise, people with T1DM treated with an interdisciplinary, multipronged approach that included more adaptable intense insulin regimes, standardized diabetes awareness, and encouraged community engagement saw a 44 percent decrease in DKA hospitalizations[11] . To improve adherence to the treatment and lower the risk of DKA, it is essential to develop future initiatives to maximize medication compliance[37]. These strategies should combine increased teaching, inspirational personal interview, and patient support systems (continuous glucose monitoring, CSII, text, e-mail messaging, and telephone support)[35]. Insulin needs to be easily accessible at a reasonable price in the world’s less developed regions[7]. The World Health Organization recognizes insulin and 0.9% saline solution as life-saving drugs [8]. The detection of DKA and the rapid access to medical facilities equipped to provide proper care depend on the training of local healthcare personnel[10].

7. Conclusion

Management of DKA there are wide areas of overlap between the different guidelines. However, there are also equally wide areas where opinions diverge. These areas where there are differences of opinion illustrate the lack of good research to help guide the best treatments for patients. Ultimately, fluid, insulin, and potassium replacements remain essential interventions for patients when clinicians handle those patients. The diagnosis and treatment of precipitating conditions, besides initiating insulin therapy, intravenous fluids, and electrolyte replacement, are all indispensable components of effective DKA. Questions on which fluid should be used and whether the use of bicarbonate alters outcomes in those with low PH. Therapeutic outcomes may be improved by adopting established guidelines and close monitoring of individual patients based on laboratory and clinical data. The

patient's care plan must include strategies for preventing DKA through organized educational programs and determining risk factors for the condition's recurrence. Further research areas also include a prospective trial of whether different severities of DKA require other treatments and whether this affects outcomes.

References

1. Große, J., et al., Incidence of diabetic ketoacidosis of new-onset type 1 diabetes in children and adolescents in different countries correlates with human development index (HDI): an updated systematic review, meta-analysis, and meta-regression. Hormone and Metabolic Research, 2018. **50**(03): p. 209-222.
2. Fredheim, S., et al., Diabetic ketoacidosis at the onset of type 1 diabetes is associated with future HbA1c levels. Diabetologia, 2013. **56**(5): p. 995-1003.
3. Manuwald, U., et al., Ketoacidosis at onset of type 1 diabetes in children up to 14 years of age and the changes over a period of 18 years in Saxony, Eastern-Germany: A population based register study. PloS one, 2019. **14**(6): p. e0218807.
4. Punnose, J., et al., Childhood and adolescent diabetes mellitus in Arabs residing in the United Arab Emirates. Diabetes research and clinical practice, 2002. **55**(1): p. 29-33.
5. Ndebele, N.F. and M. Naidoo, The management of diabetic ketoacidosis at a rural regional hospital in KwaZulu-Natal. African Journal of Primary Health Care and Family Medicine, 2018. **10**(1): p. 1-6.
6. Dhatariya, K.K., et al., Diabetic ketoacidosis. Nature Reviews Disease Primers, 2020. **6**(1): p. 1-20.
7. Agarwal, A., et al., Prognostic factors in patients hospitalized with diabetic ketoacidosis. Endocrinology and metabolism, 2016. **31**(3): p. 424-432.
8. Davies, M.J., et al., Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2018. **61**(12): p. 2461-2498.
9. Kitabchi, A.E., et al., Hyperglycemic crises in adult patients with diabetes. Diabetes care, 2009. **32**(7): p. 1335-1343.
10. Wolfsdorf, E., et al., Diabetic ketoacidosis and hyperglycemic hyperosmolar state. ISPAD clinical practice consensus guidelines 2014 compendium. Pediatric Diabetes, 2014. **15**(Suppl 20): p. 154-179.
11. Dhatariya, K.K. and J.B.D.S.f.I. Care, The management of diabetic ketoacidosis in adults—An updated guideline from the Joint British Diabetes Society for Inpatient Care. Diabetic Medicine, 2022. **39**(6): p. e14788.
12. Barski, L., et al., Euglycemic diabetic ketoacidosis. European journal of internal medicine, 2019. **63**: p. 9-14.
13. Fadini, G.P., B.M. Bonora, and A. Avogaro, SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia, 2017. **60**: p. 1385-1389.
14. Eledrisi, M.S. and A.-N. Elzouki, Management of diabetic ketoacidosis in adults: A narrative review. Saudi Journal of Medicine & Medical Sciences, 2020. **8**(3): p. 165.
15. Savage, M., et al., Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabetic medicine: a journal of the British Diabetic Association, 2011. **28**(5): p. 508-515.
16. Klocker, A., et al., Blood β-hydroxybutyrate vs. urine acetoacetate testing for the prevention and management of ketoacidosis in Type 1 diabetes: a systematic review. Diabetic medicine, 2013. **30**(7): p. 818-824.
17. Dhatariya, K., Blood ketones: measurement, interpretation, limitations, and utility in the management of diabetic ketoacidosis. The review of diabetic studies: RDS, 2016. **13**(4): p. 217.
18. Palmer, B.F. and D.J. Clegg, Electrolyte disturbances in patients with chronic alcohol-use disorder. N Engl J Med, 2017. **377**: p. 1368-1377.
19. Pasquel, F.J., et al., Clinical outcomes in patients with isolated or combined diabetic ketoacidosis and hyperosmolar hyperglycemic state: a retrospective, hospital-based cohort study. Diabetes care, 2020. **43**(2): p. 349-357.

20. ElSayed, N.A., et al., Introduction and Methodology: Standards of Care in Diabetes—2023. 2023, Am Diabetes Assoc. p. S1-S4.
21. Pasquel, F.J. and G.E. Umpierrez, Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment. Diabetes care, 2014. **37**(11): p. 3124-3131.
22. Wolfsdorf, J., et al., Diabetic ketoacidosis in children and adolescents with diabetes. Pediatr Diabetes, 2009. **10**(Suppl 12): p. 118-133.
23. Holt, R.I., Association between antipsychotic medication use and diabetes. Current diabetes reports, 2019. **19**: p. 1-10.
24. Kempegowda, P., et al., Managing hypertension in people of African origin with diabetes: Evaluation of adherence to NICE Guidelines. Primary care diabetes, 2019. **13**(3): p. 266-271.
25. Meetoo, D. and S. Alsomali, NG28: Promoting patient-centred care for adults with type 2 diabetes. Nurse Prescribing, 2016. **14**(5): p. 236-245.
26. Scott, A., Joint British Diabetes Societies (JBDS) for Inpatient Care, JBDS hyperosmolar hyperglycaemic guidelines group. Management of hyperosmolar hyperglycaemic state in adults with diabetes. Diabet Med, 2015. **32**(6): p. 714-724.
27. Shankar, P.R., Essential medicines and health products information portal. Journal of pharmacology & pharmacotherapeutics, 2014. **5**(1): p. 74.
28. Roberts, A., et al., Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabetic Medicine, 2018. **35**(8): p. 1011-1017.
29. DCCPGEC, Diabetes Canada Clinical Practice Guidelines Expert Committee (DCCPGEC), Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. 2018: Diabetes Canada.
30. Shen, T. and S. Braude, Changes in serum phosphate during treatment of diabetic ketoacidosis: predictive significance of severity of acidosis on presentation. Internal medicine journal, 2012. **42**(12): p. 1347-1350.
31. Ditzel, J. and H.-H. Lervang, Disturbance of inorganic phosphate metabolism in diabetes mellitus: clinical manifestations of phosphorus-depletion syndrome during recovery from diabetic ketoacidosis. Diabetes, metabolic syndrome and obesity: targets and therapy, 2010: p. 319-324.
32. Choi, H.S., et al., Respiratory failure in a diabetic ketoacidosis patient with severe hypophosphatemia. Annals of Pediatric Endocrinology & Metabolism, 2018. **23**(2): p. 103.
33. Kutlu, A.O., C. Kara, and S. Cetinkaya, Rhabdomyolysis without detectable myoglobulinuria due to severe hypophosphatemia in diabetic ketoacidosis. Pediatric emergency care, 2011. **27**(6): p. 537-538.
34. UK, D. End of life diabetes care. 2018; Available from: https://www.diabetes.org.uk/resources-s3/2018-03/EoL_Guidance_2018_Final.pdf.
35. Desai, D., et al., Health care utilization and burden of diabetic ketoacidosis in the US over the past decade: a nationwide analysis. Diabetes care, 2018. **41**(8): p. 1631-1638.
36. Wagner, D.V., et al., NICH at its best for diabetes at its worst: texting teens and their caregivers for better outcomes. Journal of diabetes science and technology, 2017. **11**(3): p. 468-475.
37. Charleer, S., et al., Effect of continuous glucose monitoring on glycemic control, acute admissions, and quality of life: a real-world study. The Journal of Clinical Endocrinology & Metabolism, 2018. **103**(3): p. 1224-1232.
38. Wong, J.C., et al., Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. Diabetes Care, 2014. **37**(10): p. 2702-2709.
39. Parkin, C.G., C. Graham, and J. Smolskis, Continuous glucose monitoring use in type 1 diabetes: longitudinal analysis demonstrates meaningful improvements in HbA1c and reductions in health care utilization. Journal of diabetes science and technology, 2017. **11**(3): p. 522-528.